A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

Status:
Completed

Trial end date:
2018-09-29

Target enrollment:

Participant gender:

To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in patients who achieve MR4.5

Phase 2

Novartis Pharmaceuticals